Introduction

Clinical features
The clinical features of LABD may resemble those of DH, Linear immunoglobulin A (IgA) bullous dermatosis (LABD) with a primarily pruritic papulovesicular eruption involving is a unique immunobullous disease characterized by vesextensor surfaces symmetrically. More commonly, however, icles, bullae, and erosions. It was first recognized as an entity the clinical features are more like those of BP with tense distinct from dermatitis herpetiformis (DH) or bullous vesicles and bullae developing de novo or on an urticarial pemphigoid (BP) on the basis of the immunopathologic base. 1, 4 The bullae of LABD may be somewhat linear or finding of linear IgA deposits in the basement membrane ''sausage'' like in shape. The torso and limbs are most zone (BMZ) on direct immunofluorescence (DIF) by frequently involved. Involvement of the hands, feet, periChorzelski et al. In 1979. 1 Synonyms for LABD include neum, and face may also be seen. Occasionally, there can linear IgA disease, IgA pemphigoid, and linear DH. There be generalized blistering of the body. The age of peak is a childhood variant of LABD termed chronic bullous incidence of this disease is 60-65 years with a slight female dermatosis of childhood (CBDC). CBDC has a somewhat predominance. 5 Mucous membrane involvement has been different mode of clinical presentation than that of LABD, reported to occur in up to 80% of patients. [6] [7] [8] Cicatricial but they share identical histologic and immunopathologic pemphigoid may also have IgA antibodies deposited at the characteristics, and thus are considered by most experts to BMZ in addition to IgG antibodies. A dual circulating be different clinical presentations of the same disease.
antibody response with both IgA and IgG antibodies Synonyms for CBDC include juvenile DH and juvenile predicts a worse response in this subset of cicatricial pemphigoid. LABD is an uncommon dermatosis with an pemphigoid patients. 9 estimated incidence of 0.22 and 0.5 per million of the There are two main clinical differences between adultpopulation per year in Germany and France, respectively. 2, 3 onset LABD and childhood-onset LABD or CBDC. First, CBDC occurs in children with a peak incidence of about 4.5 years, while LABD is a disease of adults. 5 Second, in Definition CBDC, there is a typical localization on the lower abdomen and perineum, while the distribution of LABD may have LABD may be diagnosed based on the following three one of two distinct patterns: 4,5 (i) involvement of extensor criteria.
surfaces with grouped papulovesicles similar to the clinical 1 The presence of a vesicular or bullous eruption, usually picture of DH; or (ii) flexural and truncal involvement with confined to the skin, but which may involve the mucous scattered vesicles and bullae similar to BP. In CBDC, the membranes.
blisters on the lower abdomen and perineum area frequently 2 The presence of a subepidermal vesicle with a predomioccur in a configuration known as a ''cluster of jewels'' nantly neutrophilic infiltrate on histology of lesional skin.
( Fig. 1) , where new lesions occur at the periphery of older 3 The presence of BMZ-specific IgA antibody deposited in blisters. The torso, hands, feet, and face may also be a linear pattern in the absence of other immunoglobulins involved. Mucosal involvement in CBDC has been reported to occur in up to 64% of patients. Occasionally, LABD on DIF of perilesional skin. scattered more evenly along the BMZ in LABD (Fig.  2) . Occasionally eosinophils may be admixed among the neutrophilic infiltrate as may be seen in some cases of BP. These findings sometimes may all be seen on different sections of the same biopsy. It is often difficult to distinguish LABD from DH or from the bullous eruption of systemic lupus erythematosus on histology alone. [15] [16] [17] 
Immunopathology
Immunofluorescence
The sine qua non for the diagnosis of LABD is the presence of BMZ-specific IgA class antibody in a linear distribution on DIF of perilesional skin in the absence of other immunoglobulins (Fig. 3a) . Without this finding a diagnosis of LABD cannot be made. Cases of LABD with IgG antibodies in addition to IgA antibodies deposited in a linear fashion at the BMZ have been reported. [18] [19] [20] [21] [22] [23] These cases immunopathologically represent an overlap of LABD and BP. These patients do not meet the strict criteria for the definition of LABD needed for the research setting. It would seem prudent, however, to treat these cases as either LABD or BP depending on which antibody response is predominant. Prospective studies are needed on these patients with BMZ antibody overlap to further define their clinical course.
Complement may occasionally be present at the BMZ in addition to IgA. There does not seem to be a significant regional variation of the deposition of antibodies in Figure 1 Blisters in a ''cluster of jewels'' configuration in a LABD. 24 Early studies suggested that circulating antibodies patient with CBDC could be detected in only a minority of patients using indirect immunofluorescence (IIF). 1, 5, 19, [25] [26] [27] These studies used intact human skin or esophageal substrates (Table 1) . The limiting titers are usually low at 1 : 10-1 : 80, but may develop an atypical eruption resembling erythema multiforme. 10, 11 much higher titers are occasionally seen. It has been shown that the use of BMZ-split human skin, as described by As LABD has been recognized as a distinct entity for only 20 years, it is difficult to assess the long-term prognosis Gammon et al., is a more sensitive substrate for the detection of these circulating IgA class antibodies. [28] [29] [30] This in this disease. Chorzelski et al. 12 have reported a mean disease duration of 5.6 years before resolution in adults.
technique separates skin in the lower lamina lucida and the tissue is then used for standard immunofluorescence. Jablonska et al. 13 have reported a mean duration of 3.9 years before resolution of CBDC. CBDC can have relapses
The majority of these antibodies bind to the epidermal side of BMZ-split human skin with a minority of these and remissions with continuation of the disease as LABD into adulthood. It is interesting to note that, during pregantibodies binding to the dermal side (Fig. 3b) . Occasionally, antibody binding to both sides of the split is observed. nancy, LABD spontaneously improves with no adverse fetal outcome observed in a series of 19 pregnancies 14 For the The antibodies are usually IgA1 subclass, but IgA2 BMZspecific antibodies have also been described in a minority purposes of the rest of this review, the term LABD includes both the adult and childhood variants of this disease.
of cases. [31] [32] [33] Free antibody has also been detected using IIF in LABD blister fluid. 34
Histopathology
Western immunoblot
In LABD, specific antibody binding has been found to Biopsy of a lesion reveals a subepidermal bulla with a superficial dermal infiltrate of neutrophils. There may be various antigens on Western immunoblot ( Table 2 ). The most well characterized of these antigens is a 97-kDa papillary microabscesses composed of neutrophils, as is typical of DH, but usually the neutrophils tend to be antigen found in a modified epidermal extract (LABD97). 35 This antigen is recognized by adult and childhood LABD
Immunoelectron microscopy
Unlike the immunofluorescent findings, where the majority sera that bind to the epidermal side of BMZ-split skin. 36 of circulating antibodies bind to the epidermal size of It has been shown that this antigen is identical to a BMZ-split skin suggesting reactivity with an antigen(s) in portion of the extracellular domain of the 180-kDa antigen the lamina lucida, there are many different patterns of recognized by circulating IgG antibodies in BP (BPAg2). 37 antibody deposition discernible on immunoelectron microThe LABD97-specific IgA antibodies do not cross-react scopy (IEM). Prost et al. 48 described the localization of with epidermal extracts containing BPAg2, unlike the IgG IgA deposits in the majority of patients studied in a ''mirror BPAg2-specific antibodies which can cross-react with image'' pattern on each side of the lamina densa, i.e. the LABD97. 38 The LABD97-specific antibodies do cross-react lamina lucida and sublamina densa. Other studies have not with a 120-kDa antigen produced in keratinocyte culroutinely found this pattern, but have found IgA deposition ture. 39, 40 It may be that the LABD97 is an alternative in the lamina lucida, lamina densa, sublamina densa, splicing product of BPAg2 or, more likely, a proteolytic in the hemidesmosome, or on the basal surface of the cleavage product with a new conformational epitope being keratinocytes (Table 3) . Indirect IEM using LABD sera formed secondary to the cleavage of BPAg2. Alternatively, with high titers of antibodies specific for LABD97 has LABD97 may represent a product of protein processing of demonstrated binding of these antibodies in the lamina BPAg2 by tissue proteases.
lucida. 54,55 Indirect IEM using LABD sera with high titers Specific binding of LABD sera that react with the dermal of antibodies specific for collagen VII shows binding to the side of BMZ-split skin to collagen VII has been described anchoring fibrils. 42,56 in case reports. [41] [42] [43] Only a minority of the dermal binding sera are, however, specific for collagen VII. We examined Disease associations the sera of 17 LABD patients who had dermal binding of IgA on IIF and none reacted with collagen VII on Western Numerous case reports link LABD to Hodgkin's disease 58 immunoblot (Egan and Zone, unpublished data, 1999).
and other B-cell lymphomas; 59, 60 whether this is a real IgA antibodies in LABD sera have been reported to bind association such as is seen in DH or simply fortuitous has to the 230-kDa bullous pemphigoid antigens (BPAg1) and yet to be determined (Table 4) . Transitional cell cancer of BPAg2. 44 Other less well-characterized antigens that have the bladder has also been reported in association with been reported as being specifically recognized by IgA LABD, as has esophageal cancer. 61, 62 The association of antibodies in LABD patients' sera include antigens of LABD and systemic lupus erythematosus (SLE) is unclear. 100 kDa, 110-120 kDa, 145 kDa, 160-180 kDa, 200 kDa, IgA can be deposited at the BMZ as part of a lupus band 220 kDa, 255 kDa, and 285 kDa (where collagen VII was seen in SLE. Also, bullous SLE is characterized by IgG antibodies reactive with collagen VII, and there may well 250 kDa). 28, 43, [45] [46] [47] 19 Non-split human skin LABD 1/34, CBDC 13/13 Mobacken et al. 26 Monkey esophagus LABD 1/9 Bhogal et al. 27 Non-split human skin LABD 2/15 Wojnarowska et al. 5 Non-split human skin LABD 5/25, CBDC 18/23 Dmochowski et al. 28 BMZ-split human skin LABD 35/46 Wojnarowska et al. 29 Non-split human skin LABD/CBDC 18/59 Wojnarowska et al. 29 BMZ-split human skin LABD/CBDC 34/59 59 Zone et al. 35 97 kDa (LABD97) Dermatitis herpetiformis 12 Yamane et al. 45 100 kDa Bladder cancer 61 Collier et al. 46 110-120 kDa Esophageal cancer 62 Marinkovich et al. 39 120 kDa Systemic lupus erythematosus 63 Yamane et al. 45 145 kDa Ulcerative colitis 64 Collier et al. 46 160-180 kDa Multiple sclerosis 66 Ghohestani et al. 44 180 kDa (BPAg2) Dermatomyositis 67 Allen et al. 43 200 kDa Crohn's disease 68 Collier et al. 46 220 kDa Hydatidiform mole 69 Ghohestani et al. 44 230 kDa (BPAg1) Rheumatoid arthritis 70 Wojnarowska et al. 47 285 kDa (collagen VII is 250 kDa in this report) Zambruno et al. 41 290 kDa (collagen VII) Drugs associated with LABD 49 SLD/AF 1/1 Iodine 85,86 * Lithium carbonate 87 Horiguchi et al. 50 LL/SBK 1/1 Bhogal et al. 27 SLD 41 SLD/AF 1/1 Hashimoto et al. 42 SLD/AF 1/1 Ishiko et al. 55 LL 5/5 *After topical contact.
Allen et al. 43 SLD/AF 2/2 Caux et al. 56 SLD/AF 1/1 Zhou et al. 57 LL 1/5, LD 1/5 patient was on high-dose immunosuppressive therapy has LL, lamina lucida; AF, anchoring fibrils; SBK, sub-basal also been described. 71 keratinocytes; SLD, sublamina densa; HD, hemidesmosome; LD, lamina densa.
Drug-induced LABD
A striking characteristic of LABD is the fact that it is frequently precipitated by drugs and that it may remit once be overlap with an IgA response developing to collagen VII in some cases. 63 LABD has been reported to develop the offending drug is stopped ( Table 4 ). The drug most frequently implicated in precipitating LABD is vancomyin the setting of DH. 12 There seems to be a real association between ulcerative colitis (UC) and LABD, although the cin, 72-75 although other drugs have been implicated. [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] The mechanism by which these drugs stimulate an IgA reason for this association is unknown; one study found UC to be present in five out of 70 (7.1%) LABD patients, antibody response to produce anti-BMZ antibodies with subsequent formation of clinical blisters is unknown. a prevalence much higher than expected; spontaneous remission of LABD coincident with a total colectomy for UC has also been described. 64, 65 Other disease associations Differential diagnosis include multiple sclerosis, 66 dermatomyositis, 67 Crohn's disease, 68 hydatidiform mole, 69 and rheumatoid arthritis. 70 Although any infectious, autoimmune, or genetic blistering skin disease can enter into the differential diagnosis of LABD developing after a cardiac transplant while the LABD, LABD needs to be differentiated clinically and to therapy as it produces cyanosis imparting a blue color to the lips and extremities. At higher doses (Ͼ200 mg/ pathologically usually from only two blistering skin diseases, DH and BP. The differential diagnosis from BP may day), it may become symptomatic with the development of weakness, headaches, and tachycardia. Other dosebe difficult clinically as both may present with tense blisters; however, on DIF, BP has linear IgG BMZ deposition, while related side-effects include a sensory and motor neuropathy which is usually reversible, toxic hepatitis and cholestatic LABD has linear IgA deposition. BP usually has a more intense infiltrate of eosinophils under the subepidermal jaundice, and hypoalbuminemia. These are rarely seen at doses of less than 200 mg/day. Idiosyncratic reactions blister with neutrophils being less prominent; the reverse is true for LABD. Distinguishing LABD from DH is usually include psychiatric symptoms, an infectious mononucleosislike syndrome, exfoliative dermatitis, erythema multiforme, not difficult clinically as only a minority of LABD cases present with a DH-like eruption of intensely pruritic erythema nodosum, and urticaria. The most feared idiosyncratic reaction is aplastic anemia which usually occurs in papulovesicles and erosions on extensor surfaces. The histology of LABD and DH can be identical with neutrothe first 2-12 weeks of therapy.
Patients on dapsone therapy should have the following phils packing the dermal papillae under subepidermal blisters. Because both diseases are characterized by IgA laboratory follow-up: (i) baseline complete blood count (CBC) and liver function tests and a G-6-PD level if deposits on DIF, it is easy to understand why it took so long to separate LABD as a clinical entity from DH. There indicated; (ii) the CBC should be checked weekly for the first month, monthly for the next 5 months, and are some important differences between the two diseases: (i) DH is associated with a gluten-sensitive enteropathy in semiannually thereafter; (iii) a chemistry profile should be obtained at 6 months and then annually to monitor for almost all cases which responds to a gluten-free diet, 93 whereas in LABD there is no such association and no possible hepatotoxicity, changes in renal function, and hypoalbuminemia; (iv) patients should be made aware of improvement with a gluten-free diet; 94 (ii) DH is closely associated with the HLA-B8-DR3 haplotype but there is the development of cyanosis and hemolytic anemia to allay anxiety when these expected side-effects occur. no association with LABD; 95 (iii) the IgA found in the skin of DH patients is in granular deposits in the dermal papillae If the patient is intolerant of dapsone, sulfapyridine may be used, usually at a dose of 1.0-1.5 g/day; however, its and no circulating BMZ-specific antibodies have been detected in DH. 96 Thus while DH and LABD share some absorption is erratic, reducing its clinical usefulness. It is often worthwhile to use small doses of corticosteroids (5-features, they differ significantly with regard to immunopathology.
15 mg/day) in addition to dapsone or sulfapyridine in cases where high-dose dapsone or sulfapyridine alone do not adequately control the disease. 1,97, 98 Other therapies that Treatment have been reported to be of benefit in LABD include colchicine, 99 and a combination of tetracycline and nicotiAs with DH, the therapy of choice in LABD is dapsone. It should be started at a low dose (25 mg/day adults, 6.25 mg/ namide. 100 day children) and increased as tolerated at weekly intervals to a maintenance dose (100-200 mg/day adults, 25-50 mg/ Conclusions day children). Dapsone exhibits good bioavailability, but serum levels can have a wide variation; therefore, measuring LABD is a unique immunobullous skin disease characterized by the linear deposition of BMZ-specific IgA on DIF. serum dapsone levels as a guide to therapy has little value. There is wide variability in the half-life of dapsone (10- Clinically, it can be separated into an adult and childhood form. Immunopathologically, the IgA antibodies have been 50 h), but the vast majority of patients are best managed on a single daily dose. Hemolysis is the most common sidereported to react with numerous basement membrane antigens. The best characterized of these antigens are effect of treatment. Dapsone is a strong oxidizer and produces a dose-related oxidant stress on normal aging red LABD97 and collagen VII. LABD is often precipitated by drugs. LABD needs to be differentiated from BP and DH cells. Initial reduction of hemoglobin by 2-3 g is common, but subsequent partial compensation by reticulocytosis is clinically and immunopathologically. The therapy of choice for LABD is dapsone. the rule. It may produce severe hemolysis in patients with glucose-6-phosphate-dehydrogenase (G-6-PD) deficiency. Blacks, Asians, and Caucasians of southern Mediterranean Acknowledgments descent should be screened for G-6-PD deficiency before starting dapsone therapy.
Supported 
